Ignite Creation Date:
2024-05-05 @ 10:33 PM
Last Modification Date:
2024-10-26 @ 10:20 AM
Study NCT ID:
NCT01135394
Status:
COMPLETED
Last Update Posted:
2024-03-15
First Post:
2010-06-01
Brief Title:
Pharmacogenomics of Thiazolidinediones
Sponsor:
University of Maryland Baltimore
Organization:
University of Maryland Baltimore
Study Overview
Official Title:
Pharmacogenomics of Thiazolidinediones
Status:
COMPLETED
Status Verified Date:
2024-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
PPAR
Brief Summary:
The purpose of this study is to determine predictors of response to pioglitazone an anti-diabetic medication The investigators know from randomized clinical trials that some 30 of patients do not respond to this type of medication There is presently no way to identify this group of patients leading to unnecessary drug exposure and medication costs
Detailed Description:
In phase I subjects who are eligible based on height and weight and general health information will sign informed consent In phase II subjects will be screened to ensure that they fit the inclusionexclusion criteria including an oral glucose tolerance test Other blood tests will be performed to check complete blood count lipids liver functions and electrolytes
Qualifying volunteers will enter phase III which will consist of outpatient radioimaging and body composition metabolic testing intravenous glucose tolerance test and tissue biopsies Blood will also be drawn for genetic testing and for microarray studies of leukocytes Written medication information and instructions for pioglitazone discharge instructions and satisfaction surveys following the tissue biopsy procedures will be given to subjects during the study During phase IV subjects will begin pioglitazone therapy Every 4 weeks throughout the drug intervention glycemic control lipoprotein profile and weight will be monitored After 12 weeks of pioglitazone therapy the X-ray and magnetic resonance MR measurements of body composition the biopsies and the metabolic tests performed during phase III will be repeated phase V and blood will be drawn for microarray studies of leukocytes
Thereafter subjects will have the option to be enrolled in a 10 week behavioral weight loss program phase VI Following the 10-week weight loss program a few outcome measurements will be repeated phase VII
Throughout the study Women of Child Bearing Potential WCBP will have human human chorionic gonadotrophin HCG urine pregnancy tests Pregnancy tests will only be performed on Women of childbearing potential meaning women who are pre-menopausal and who have not had surgical sterilization Women who have not had a hysterectomy or tubal ligation at least six months prior to signing informed consent or have been postmenopausal for at least one year will be instructed to practice one of the following methods of birth control throughout the study oral transdermal or implantable hormonal contraceptives intrauterine device diaphragm plus spermicide condom plus spermicide or abstinence Pioglitazone may reduce the effectiveness of some hormonal types of contraceptives Women using hormonal methods of birth control will be advised to use a barrier method as well Female subjects are informed to notify the investigators immediately if they think they might have become pregnant during the study
Participants who are eligible have 10 visits over an approximate 15-week period Participants can choose to participate in an optional weight management program for an additional 10 weeks after treatment and before their final visit
Qualifying volunteers will enter phase III which will consist of outpatient radioimaging and body composition metabolic testing intravenous glucose tolerance test and tissue biopsies Blood will also be drawn for genetic testing and for microarray studies of leukocytes Written medication information and instructions for pioglitazone discharge instructions and satisfaction surveys following the tissue biopsy procedures will be given to subjects during the study During phase IV subjects will begin pioglitazone therapy Every 4 weeks throughout the drug intervention glycemic control lipoprotein profile and weight will be monitored After 12 weeks of pioglitazone therapy the X-ray and magnetic resonance MR measurements of body composition the biopsies and the metabolic tests performed during phase III will be repeated phase V and blood will be drawn for microarray studies of leukocytes
Thereafter subjects will have the option to be enrolled in a 10 week behavioral weight loss program phase VI Following the 10-week weight loss program a few outcome measurements will be repeated phase VII
Throughout the study Women of Child Bearing Potential WCBP will have human human chorionic gonadotrophin HCG urine pregnancy tests Pregnancy tests will only be performed on Women of childbearing potential meaning women who are pre-menopausal and who have not had surgical sterilization Women who have not had a hysterectomy or tubal ligation at least six months prior to signing informed consent or have been postmenopausal for at least one year will be instructed to practice one of the following methods of birth control throughout the study oral transdermal or implantable hormonal contraceptives intrauterine device diaphragm plus spermicide condom plus spermicide or abstinence Pioglitazone may reduce the effectiveness of some hormonal types of contraceptives Women using hormonal methods of birth control will be advised to use a barrier method as well Female subjects are informed to notify the investigators immediately if they think they might have become pregnant during the study
Participants who are eligible have 10 visits over an approximate 15-week period Participants can choose to participate in an optional weight management program for an additional 10 weeks after treatment and before their final visit
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| R01DK074828 | NIH | None | httpsreporternihgovquickSearchR01DK074828 |